Drug Shortage Report for TEVA-NABILONE

Last updated on 2023-04-28 History
Report ID 169973
Drug Identification Number 02392925
Brand name TEVA-NABILONE
Common or Proper name TEVA-NABILONE
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) NABILONE
Strength(s) 0.25MG
Dosage form(s) CAPSULE
Route of administration ORAL ORAL
Packaging size 50
ATC code A04AD
ATC description ANTIEMETICS AND ANTINAUSEANTS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-09-22
Estimated end date 2023-03-10
Actual end date 2023-04-27
Shortage status Resolved
Updated date 2023-04-28
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2022-09-22 English Compare
v2 2022-09-22 French Compare
v3 2022-09-23 English Compare
v4 2022-09-30 English Compare
v5 2022-09-30 French Compare
v6 2022-10-17 English Compare
v7 2022-10-17 French Compare
v8 2022-11-14 English Compare
v9 2022-11-14 French Compare
v10 2022-12-01 English Compare
v11 2022-12-01 French Compare
v12 2022-12-08 English Compare
v13 2022-12-08 French Compare
v14 2023-01-12 English Compare
v15 2023-01-12 French Compare
v16 2023-02-02 English Compare
v17 2023-02-02 French Compare
v18 2023-04-27 English Compare
v19 2023-04-27 French Compare
v20 2023-04-28 English Compare

Showing 1 to 20 of 20